1
|
Brandão-Souza C, Amorim MHC, Zandonade E, Fustinoni SM, Schirmer J. Completude dos prontuários de idosas com câncer de mama: estudo de tendência. ACTA PAUL ENFERM 2019. [DOI: 10.1590/1982-0194201900057] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
Resumo Objetivo Avaliar a completude e a tendência de completude de dados dos prontuários de idosas acometidas por câncer de mama, diagnosticadas e atendidas entre os anos de 2001 e 2006 em um centro de referência em saúde da mulher do Estado de São Paulo. Métodos Estudo descritivo analítico baseado em dados secundários. Para análise da não completude, utilizou-se a classificação: excelente (< 5%), bom (5 a 10%), regular (10 a 20%), ruim (20 a 50%) e muito ruim (≥50%). Resultados Variáveis socioeconômicas e demográficas, bem como as de fatores de risco e comportamentais predominaram dentre as classificadas como regular, ruim e muito ruim. Os melhores escores foram das variáveis pós-tratamento, seguidas pelas relacionadas ao diagnóstico e ao tratamento. A única variável com tendência de não completude decrescente foi história familiar de câncer de mama (p = 0,05). Apresentaram tendência de não completude crescente: raça/cor (p = 0,01), anos de estudo (p = 0,01), uso de contraceptivos orais (p = 0,002), tempo de uso de contraceptivos orais (p = 0,002), reposição hormonal (p = 0,007) e amamentação (p = 0,004). Conclusão Dentre as variáveis classificadas como regular, ruim e muito ruim, a tendência de completude predominou como constante, seguida pela tendência crescente de não completude; apenas uma variável apresentou melhora da tendência de completude. O registro completo dos dados em prontuário é tarefa inerente de toda a equipe de saúde, primordial para estabelecer protocolos da assistência, no desenvolvimento de pesquisa, bem como na implementação de políticas públicas de saúde.
Collapse
|
2
|
Evans DG, Harkness EF, Howell A, Wilson M, Hurley E, Holmen MM, Tharmaratnam KU, Hagen AI, Lim Y, Maxwell AJ, Moller P. Intensive breast screening in BRCA2 mutation carriers is associated with reduced breast cancer specific and all cause mortality. Hered Cancer Clin Pract 2016; 14:8. [PMID: 27087880 PMCID: PMC4832454 DOI: 10.1186/s13053-016-0048-3] [Citation(s) in RCA: 40] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2016] [Accepted: 04/05/2016] [Indexed: 11/13/2022] Open
Abstract
Background The addition of annual MRI screening to mammography has heightened optimism that intensive screening along with improved treatments may substantially improve life expectancy of women at high risk of breast cancer. However, survival data from BRCA2 mutation carriers undergoing intensive combined breast screening are scarce. Methods We have collated the results of screening with either annual mammography or mammography with MRI in female BRCA2 mutation carriers in Manchester and Oslo and use a Manchester control group of BRCA2 mutation carriers who had their first breast cancer diagnosed without intensive screening. Results Eighty-seven BRCA2 mutation carriers had undergone combined (n = 34) or mammography (n = 53) screening compared to 274 without such intensive screening. Ten year breast cancer specific survival was 100 % in the combined group (95 % CI 82.5–100 %) and 85.5 % (95 % CI 72.6–98.4 %) in the mammography group compared to 74.6 % (95 % CI 66.6–82.6 %) in the control group. Better survival was driven by lymph node status (negative in 67 % of screened vs 39 % of unscreened women; p < 0.001) and a significantly greater proportion of intensively screened women had invasive breast cancers <2 cm at diagnosis (74.6 % vs 50.4 %; p = 0.002). Conclusion Intensive combined breast cancer screening with annual MRI and mammography appears to improve survival from breast cancer in BRCA2 mutation carriers. Data from larger groups are required to confirm the effectiveness of combined screening in BRCA2 carriers.
Collapse
Affiliation(s)
- D G Evans
- Genesis Breast Cancer Prevention Centre and Nightingale Breast Screening Centre, University Hospital of South Manchester, Southmoor Road, Wythenshawe, Manchester, M23 9LT UK ; Genomic Medicine, St Mary's Hospital, Oxford Road, Manchester Academic Health Sciences Centre, University of Manchester Institute of Human Development, Central, Manchester Foundation Trust, Manchester, M13 9WL UK
| | - E F Harkness
- Genesis Breast Cancer Prevention Centre and Nightingale Breast Screening Centre, University Hospital of South Manchester, Southmoor Road, Wythenshawe, Manchester, M23 9LT UK ; Centre for Imaging Sciences, Institute of Population Health, University of Manchester, Oxford Road, Manchester, M13 9PL UK
| | - A Howell
- Genesis Breast Cancer Prevention Centre and Nightingale Breast Screening Centre, University Hospital of South Manchester, Southmoor Road, Wythenshawe, Manchester, M23 9LT UK
| | - M Wilson
- Genesis Breast Cancer Prevention Centre and Nightingale Breast Screening Centre, University Hospital of South Manchester, Southmoor Road, Wythenshawe, Manchester, M23 9LT UK
| | - E Hurley
- Genesis Breast Cancer Prevention Centre and Nightingale Breast Screening Centre, University Hospital of South Manchester, Southmoor Road, Wythenshawe, Manchester, M23 9LT UK
| | - M M Holmen
- Department of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, Norway
| | - K U Tharmaratnam
- Department of Mathematics, University of Oslo, Blindern, Oslo, Norway
| | - A I Hagen
- Department of Breast and Endocrine Surgery, Trondheim University Hospital, Trondheim, Norway ; Department of Laboratory Medicine, Children's and Women's Health, Faculty of Medicine, Norwegian University of Science and Technology, Trondheim, Norway
| | - Y Lim
- Genesis Breast Cancer Prevention Centre and Nightingale Breast Screening Centre, University Hospital of South Manchester, Southmoor Road, Wythenshawe, Manchester, M23 9LT UK
| | - A J Maxwell
- Genesis Breast Cancer Prevention Centre and Nightingale Breast Screening Centre, University Hospital of South Manchester, Southmoor Road, Wythenshawe, Manchester, M23 9LT UK
| | - P Moller
- Inherited Cancer Research Group, The Norwegian Radium Hospital, Department for Medical Genetics, Oslo University Hospital, Oslo, Norway ; Department of Tumour Biology, Institute of Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway ; Department of Human Medicine, Universität Witten/Herdecke, Witten, Germany
| |
Collapse
|